BioCentury | Jun 25, 2007
Regulation

Shortness of breath

Sepracor Inc. may be about to lose more than a quarter of the market for its Xopenex levalbuterol as the result of a technicality in the Medicare law - and the Centers for Medicare & Medicare...
Items per page:
1 - 1 of 1